Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized 4-week study of GRT6005 for moderate to severe knee osteoarthritis pain
2010-022556-23Phase 2Completed
- Sponsor
- Grünenthal GmbH
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cebranopadol in knee osteoarthritis (OA) (4 arms), sponsored by Grünenthal GmbH. Primary endpoint: Change from baseline in pain intensity score during the last treatment week. Started Feb 2011; status: completed.
02
Drugs
cebranopadol
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2010-022556-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022556-23.